Immix Biopharma, Inc. (IMMX)
NCM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Immix Biopharma, Inc. — DEF 14A Filing
Here's a clear breakdown of Immix Biopharma's (IMMX) proxy statement, focusing on what matters most to shareholders. # 🧾 What This Document Is This is a **Definitive Proxy Statement (DEF 14A)**. It's like an "invitation and instruction manual" for Immix Biopharma's 2026 Annual Meeting of Stockhold
Immix Biopharma, Inc. — ARS Filing
# 🧾 What This Document Is This is Immix Biopharma's **Annual Report (ARS)** for the fiscal year ended December 31, 2023. Think of it as the company's yearly "check-up" report to the SEC and its investors. It's a comprehensive look at their business, financial health, and progress on their goals ov
SEC filings
All filings →Insider trades
All insider trades →Immix Biopharma, Inc. has no reported insider trades in the last 90 days.